The Way Forward

A Message From Our Executive Chairman

When we began this journey back in 2013 in the world-renown MD Anderson, we knew that the technology had the potential to change the way tattoos would be removed for the foreseeable future.

Fast-forward to today and that’s exactly what our clinical data has demonstrated.

As we prepare for the commercialization of our RAP technology for tattoo removal, we are in the early stages of research for two completely different indications: Subcutaneous Fat and Cellulite Reduction.

The market for reducing subcutaneous fat is considered an enormous opportunity, as evidenced by the recent acquisition of Zeltiq (CoolSculpt) for $2.4 billion. Based on preclinical testing, we believe Soliton’s RAP has the potential to accelerate existing fat reduction technologies and improve their efficacy.

The preclinical data that we have produced for this indication caught the attention of a multi-billion dollar global aesthetics company and since then, they have asked us to test the combination of our technology with theirs.

Current technologies for subcutaneous fat reduction have gained strong market acceptance, but they typically only achieve 20 to 30% reduction.  If Soliton RAP can be shown to significantly increase that level of efficacy, it would represent a major breakthrough for the fat reduction market.

Given the magnitude of the opportunity here, it is no accident that our scientific advisory board is comprised of mostly former medical advisory board members from Zeltiq (Coolsculpt).

The other indication that has us extremely excited is the potential to reduce the appearance of cellulite.

Cellulite is a complex condition that occurs in nearly 80% of all women because of the uniqueness of their skin’s structure.  Women’s skin is more flexible than men’s probably owing to the need for women to accommodate childbirth.  However, as this flexible structure weakens with age, subcutaneous fat can begin to push up through openings in the structure, creating the lumpiness associated with cellulite.  A critical component of the structure needed to prevent this is collagen, which is produced by fibroblasts in the dermis.

We have discovered in preclinical testing that Soliton’s RAP is capable of inducing fibroblasts to increase their production of collagen and we believe that our RAP technology could become the first non-invasive, virtually painless method for reducing cellulite.

What you see here is a side-by-side comparison of skin, the biopsy on the left is from an untreated area and the one on the right has been treated given just one 2-minute treatment of Soliton RAP.

The samples are both prepared with a stain that turns purple when in contact with old collagen and blue when in contact with new collagen.  You can see from this comparison that the sample treated with Soliton RAP is filled with new collagen.

Our expectation is that as the return of greater collagen structure re-plumps the skin, adds structure and promotes more even skin surface, the appearance of cellulite should be noticeably reduced.

We are planning to conduct clinical trials in humans in the near future.

Beyond these two potential new indications, we believe our RAP technology has the potential to impact a wide range of conditions.  The following graphic highlights just some of the areas for possible future expansion.

Soliton was born and raised on science.  We spent 5 years and over $25 million in hardcore research and development to gain a deeper understanding of our targeted indications and develop breakthrough technology capable of changing the game in aesthetic devices.  We intend to continue pursuing solid science as we reach beyond tattoo removal to allow RAP to develop as a true technology platform.  The future is bright!

Respectfully yours,


Wally Klemp
Executive Chairman
Soliton Inc.